Cargando…

The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease

BACKGROUND: Graves’ disease (GD) is one of the most common autoimmune thyroid diseases (AITDs) in humans, and thyrotropin receptor antibody (TRAb) is a characterized autoantibody in GD. The use of radioactive iodine therapy (RAI) for GD treatment is increasing. OBJECTIVES: We studied the biological...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Ya, Du, Wen-Hua, Zhang, Cao-Xu, Zhao, Shuang-Xia, Song, Huai-Dong, Gao, Guan-Qi, Dong, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630916/
https://www.ncbi.nlm.nih.gov/pubmed/34847904
http://dx.doi.org/10.1186/s12902-021-00905-4
_version_ 1784607456837500928
author Fang, Ya
Du, Wen-Hua
Zhang, Cao-Xu
Zhao, Shuang-Xia
Song, Huai-Dong
Gao, Guan-Qi
Dong, Mei
author_facet Fang, Ya
Du, Wen-Hua
Zhang, Cao-Xu
Zhao, Shuang-Xia
Song, Huai-Dong
Gao, Guan-Qi
Dong, Mei
author_sort Fang, Ya
collection PubMed
description BACKGROUND: Graves’ disease (GD) is one of the most common autoimmune thyroid diseases (AITDs) in humans, and thyrotropin receptor antibody (TRAb) is a characterized autoantibody in GD. The use of radioactive iodine therapy (RAI) for GD treatment is increasing. OBJECTIVES: We studied the biological properties of TRAb and evaluated the effect of RAI therapy on TRAb in GD patients. METHODS: In total, 225 patients (22 onset GD patients without (131)I therapy, 203 GD patients treated with (131)I therapy) and 20 healthy individuals as normal controls were included in this study. Clinical assessments were performed, and we examined in vitro the biological properties of TRAb in the 22 onset GD patients and 20 controls as well as 84 GD patients with (131)I therapy. RESULTS: Serum TRAb and thyroid peroxidase antibody (TPOAb) levels increased in the initial year of RAI treatment, and both antibodies decreased gradually after one year. After 5 years from radioiodine treatment, TRAb and TPOAb levels decreased in 88% and 65% of GD patients, respectively. The proportion of patients positive for thyroid-stimulatory antibody (TSAb) was significantly higher in the 7–12-month group, and thyroid-blocking antibody (TBAb) levels were elevated after one year in half of the patients who received (131)I treatment. CONCLUSIONS: Treatment of GD patients with radioiodine increased TPOAb and TRAb (their main biological properties were TSAbs) within the first year after therapy, and the main biological properties of elevated TRAb were TBAbs after 1 year.
format Online
Article
Text
id pubmed-8630916
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86309162021-12-01 The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease Fang, Ya Du, Wen-Hua Zhang, Cao-Xu Zhao, Shuang-Xia Song, Huai-Dong Gao, Guan-Qi Dong, Mei BMC Endocr Disord Research BACKGROUND: Graves’ disease (GD) is one of the most common autoimmune thyroid diseases (AITDs) in humans, and thyrotropin receptor antibody (TRAb) is a characterized autoantibody in GD. The use of radioactive iodine therapy (RAI) for GD treatment is increasing. OBJECTIVES: We studied the biological properties of TRAb and evaluated the effect of RAI therapy on TRAb in GD patients. METHODS: In total, 225 patients (22 onset GD patients without (131)I therapy, 203 GD patients treated with (131)I therapy) and 20 healthy individuals as normal controls were included in this study. Clinical assessments were performed, and we examined in vitro the biological properties of TRAb in the 22 onset GD patients and 20 controls as well as 84 GD patients with (131)I therapy. RESULTS: Serum TRAb and thyroid peroxidase antibody (TPOAb) levels increased in the initial year of RAI treatment, and both antibodies decreased gradually after one year. After 5 years from radioiodine treatment, TRAb and TPOAb levels decreased in 88% and 65% of GD patients, respectively. The proportion of patients positive for thyroid-stimulatory antibody (TSAb) was significantly higher in the 7–12-month group, and thyroid-blocking antibody (TBAb) levels were elevated after one year in half of the patients who received (131)I treatment. CONCLUSIONS: Treatment of GD patients with radioiodine increased TPOAb and TRAb (their main biological properties were TSAbs) within the first year after therapy, and the main biological properties of elevated TRAb were TBAbs after 1 year. BioMed Central 2021-11-30 /pmc/articles/PMC8630916/ /pubmed/34847904 http://dx.doi.org/10.1186/s12902-021-00905-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Fang, Ya
Du, Wen-Hua
Zhang, Cao-Xu
Zhao, Shuang-Xia
Song, Huai-Dong
Gao, Guan-Qi
Dong, Mei
The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
title The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
title_full The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
title_fullStr The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
title_full_unstemmed The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
title_short The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
title_sort effect of radioiodine treatment on the characteristics of trab in graves’ disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630916/
https://www.ncbi.nlm.nih.gov/pubmed/34847904
http://dx.doi.org/10.1186/s12902-021-00905-4
work_keys_str_mv AT fangya theeffectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT duwenhua theeffectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT zhangcaoxu theeffectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT zhaoshuangxia theeffectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT songhuaidong theeffectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT gaoguanqi theeffectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT dongmei theeffectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT fangya effectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT duwenhua effectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT zhangcaoxu effectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT zhaoshuangxia effectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT songhuaidong effectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT gaoguanqi effectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease
AT dongmei effectofradioiodinetreatmentonthecharacteristicsoftrabingravesdisease